Schizophrenia Market Expected to rise, 2034 | Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion/PsychoGenics, Otsuka Pharmaceuticals, Neurocrine Biosc

The Schizophrenia market growth is driven by factors like increase in the prevalence of Schizophrenia, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Schizophrenia market report [https://www.delveinsight.com/report-store/schizophrenia-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Schizophrenia market size, share, Schizophrenia epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Schizophrenia market size growth forward.

Some of the key highlights from the Schizophrenia Market Insights Report:

*
Several key pharmaceutical companies, including Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion/PsychoGenics, Otsuka Pharmaceuticals, Neurocrine Biosciences, Takeda, Minerva Neurosciences, Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics, and others, are developing novel products to improve the Schizophrenia treatment outlook.

*
The Schizophrenia market is expected to grow as awareness of the condition increases and more effective treatments are developed. The number of schizophrenia cases is projected to rise from 2024 to 2034 due to greater awareness of mental health and advancements in diagnostic methods. In the early stages of schizophrenia, symptoms are often vague and overlap with other mental health issues or normal behavioral changes, which can delay diagnosis due to stigma and fear. This gap between prevalence and diagnosis often leads to delays in treatment.

*
Currently, there is no cure for schizophrenia, and treatment primarily focuses on symptom management and relapse prevention. In some cases, hospitalization may be required. The main treatment approaches include medication and psychosocial therapy. Pharmacological treatments play a key role, with both mono and combination therapies available to address symptoms.

*
Antipsychotic drugs, which are central to treatment, dominate the market and are divided into first- and second-generation medications. Second-generation antipsychotics (SGAs) are preferred over first-generation antipsychotics (FGAs) and are commonly prescribed in the US, including FDA-approved medications such as CAPLYTA (lumateperone), VRAYLAR (cariprazine), LYBALVI (olanzapine and samidorphan), REXULTI (brexpiprazole), and LATUDA (lurasidone hydrochloride). Other oral therapies like FANAPT and ABILIFY MYCITE are also used.

*
The competitive landscape is evolving with the approval of generic versions of drugs like LATUDA, leading to a significant decrease in its market revenue during the forecast period. Recent studies suggest that long-acting injectables (LAIs) may be more effective than oral medications in reducing hospitalization risk. Injectables such as ARISTADA (aripiprazole lauroxil), ABILIFY MAINTENA (aripiprazole), INVEGA products, RISPERDAL CONSTA (risperidone), and PERSERIS (risperidone) are important in this area.

*
Although there have been significant improvements in schizophrenia treatments, non-adherence remains a challenge, contributing to higher morbidity and mortality. Established atypical antipsychotics are effective for managing positive symptoms but have limited impact on cognitive and negative symptoms.

*
In 2022, the US had the largest schizophrenia market size among the 7MM, with a value of approximately USD 5,749.0 million, and this is expected to grow further by 2034. Increased research and development, along with a better understanding of the disease, have driven advancements in clinical knowledge. Emerging therapies like Ulotaront (SEP-363856) from Sumitomo Pharma/Otsuka Pharmaceuticals and Reviva Pharmaceuticals' brilaroxazine (RP5063) are expected to enter the market during the forecast period, bringing new players to the treatment landscape.

*
Brilaroxazine (RP5063), a new compound with strong selectivity for serotonin and dopamine receptors, is anticipated to be introduced to the US market in 2026, potentially challenging current treatments. Additionally, BMS's novel drug, KarXT-now named COBENFY-received FDA approval on September 26, 2024, as the first muscarinic agonist for schizophrenia, marking the first new treatment class for the condition in 35 years since CLOZARIL (clozapine) was approved.

*
As per DelveInsight analysis, the Schizophrenia market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Schizophrenia Market Landscape [https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Schizophrenia Overview

Schizophrenia is a complex, long-lasting, and severe mental disorder that involves a variety of psychological symptoms, including distortions in perception, thinking, emotions, and behavior. Contrary to common misconceptions, schizophrenia is not a condition of split or multiple personalities. It is also not caused by childhood trauma, poor parenting, or a lack of willpower, and its symptoms can vary significantly between individuals. Furthermore, most people with schizophrenia are not violent and do not pose a risk to others.

Schizophrenia affects about 1% of the population in the United States, disrupting thinking, emotions, decision-making, and social interactions. It typically emerges in the late teens to early twenties in men and late twenties to early thirties in women. Both genetic and environmental factors contribute to its onset, with a strong hereditary link.

Risk factors for schizophrenia include genetic predisposition, changes in brain structure and function, viral infections, and immune disorders. As multiple factors may contribute to the development of schizophrenia, its exact cause remains unknown in individual cases. Since schizophrenia encompasses a range of disorders, variations in its causes across different cases are expected.

Symptoms of schizophrenia are typically categorized into three types: psychotic (such as hallucinations and delusions), negative (such as a lack of motivation and social withdrawal), and cognitive (such as problems with attention and memory). Hallucinations involve sensing things that are not present, such as hearing voices, while delusions are strong, false beliefs. Negative symptoms include a loss of motivation and social withdrawal, and cognitive symptoms can impair attention and memory, making everyday tasks difficult.

Do you know the treatment paradigms for different countries? Download our Schizophrenia Market Sample Report [https://www.delveinsight.com/report-store/schizophrenia-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Recent developments in the Schizophrenia market:

*
In January 2025, Boehringer announced that its Phase III CONNEX program for the investigational schizophrenia drug iclepertin failed to meet its primary and key secondary endpoints. After six months, the drug showed no significant cognitive or functional improvements compared to a placebo across all three studies.

*
In January 2025, Johnson & Johnson and Intra-Cellular Therapies reached a definitive agreement for Johnson & Johnson to acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company specializing in CNS disorder treatments, for $134.00 per share in cash, with an overall equity value of approximately $14.6 billion.

*
On November 11, 2024, AbbVie announced that its two Phase 2 EMPOWER trials of emraclidine, a once-daily oral monotherapy for adults with schizophrenia and acute psychotic symptoms, did not meet the primary endpoint. The trials showed no significant improvement in the Positive and Negative Syndrome Scale (PANSS) total score compared to a placebo at week 6.

*
On September 26, 2024, Bristol Myers Squibb (BMY) announced that the U.S. Food and Drug Administration (FDA) approved COBENFY Trademark (xanomeline and trospium chloride), an oral treatment for schizophrenia in adults. This approval is particularly significant as it introduces the first new drug class for schizophrenia in 35 years, targeting M1 and M4 receptors in the brain without blocking D2 receptors, potentially changing the treatment landscape for the disorder. CEO Chris Boerner, PhD, highlighted the importance of this novel approach in neuropsychiatry.

*
On September 21, 2024, Teva Pharmaceuticals reported positive results from its Phase 3 SOLARIS trial for TEV-749, a subcutaneous injection for schizophrenia. The trial showed significant reductions in the PANSS total score by week 8 and improvements in key secondary endpoints, with no instances of post-injection delirium/sedation syndrome (PDSS). These results were presented at the 37th Annual European College of Neuropsychopharmacology Congress in Milan, Italy.

*
On September 12, 2024, BMO Capital Markets analyst Evan Seigerman expressed concerns about Neurocrine Biosciences' development strategy after inconsistent results from mid-stage trials of luvadaxistat. Neurocrine announced it would discontinue the development of this investigational schizophrenia drug after the Phase II ERUDITE study failed to meet its primary endpoint of cognitive improvement in over 200 patients. The company noted that luvadaxistat did not replicate the cognitive benefits observed in the earlier INTERACT study, where a 50-mg dose showed significant improvements.

Schizophrenia Epidemiology Insights

*
In 2022, the United States represented approximately 37.20% of all diagnosed prevalent schizophrenia cases among the 7MM, with around 1,412,470 cases. These numbers are expected to rise during the study period (2020-2034).

*
According to DelveInsight's analysis, the EU4 countries and the UK had about 1,588,816 diagnosed prevalent cases of schizophrenia in 2022, and this figure is anticipated to change over the study period (2020-2034).

*
Within the EU4 and the UK, Germany had the highest number of schizophrenia cases, accounting for nearly 28.50% of the total cases, followed by the UK and France, while Spain had the fewest cases in 2022.

*
DelveInsight's epidemiology model estimates that schizophrenia has a higher prevalence in males than females in the US. Of the total diagnosed prevalent cases in the US in 2022, approximately 53.63% were males and 46.37% were females.

Schizophrenia Epidemiology Segmentation

DelveInsight's Schizophrenia market report is prepared on the basis of an epidemiology model. It offers comprehensive insights to the Schizophrenia historical patient pools and forecasted Schizophrenia patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Schizophrenia Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

*
Schizophrenia Prevalence

*
Age-Specific Schizophrenia Prevalence

*
Gender-Specific Schizophrenia Prevalence

*
Diagnosed and Treatable Cases of Schizophrenia

Visit for more @ Schizophrenia Epidemiological Insights [https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Schizophrenia Market Outlook

Schizophrenia treatment generally involves a combination of medication and psychosocial interventions to manage symptoms. Antipsychotic drugs, divided into first-generation (FGAs) and second-generation (SGAs), are commonly used as first-line treatments. In some cases, a mix of antipsychotics and antiepileptics is used. Both oral antipsychotics (OAPs) and long-acting injectables (LAIs) are available for each type. Clinicians often use both FGAs and SGAs to address the diverse symptoms of schizophrenia.

FGAs, such as chlorpromazine and haloperidol, are effective but carry a higher risk of neurological side effects, including tardive dyskinesia. As a result, SGAs, like brexpiprazole (REXULTI), lumateperone (CAPLYTA), and lurasidone (LATUDA), are preferred due to their lower risk of serious side effects. These medications target neurotransmitters like dopamine and serotonin, with each offering specific benefits for managing symptoms.

Brexpiprazole (REXULTI) works by modulating dopamine and serotonin receptors to alleviate symptoms of schizophrenia. Lumateperone (CAPLYTA), a serotonin-dopamine activity modulator, has a unique mechanism that may offer better efficacy and tolerability than traditional antipsychotics. These medications are part of the evolving treatment landscape, addressing the varied needs of schizophrenia patients.

Schizophrenia Marketed Drugs

*
ABILIFY MAINTENA (aripiprazole): Otsuka Pharmaceutical/Lundbeck

*
UZEDY (risperidone): Teva Pharmaceuticals/MedinCell

Schizophrenia Emerging Drugs

*
Ulotaront (SEP-363856): Sumitomo Pharma/Otsuka Pharmaceuticals

*
Brilaroxazine (RP-5063): Reviva Pharmaceuticals

Schizophrenia Key Companies

*
Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion/PsychoGenics, Otsuka Pharmaceuticals, Neurocrine Biosciences, Takeda, Minerva Neurosciences, Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics, and others

For more information, visit Schizophrenia Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/schizophrenia-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Schizophrenia Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Schizophrenia, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Schizophrenia epidemiology in the 7MM

*
Schizophrenia marketed and emerging therapies

*
Schizophrenia companies

*
Schizophrenia market drivers and barriers

Table of Contents:

1 Schizophrenia Market Key Comprehensive Insights

2 Schizophrenia Market Report Introduction

3 Competitive Intelligence Analysis for Schizophrenia

4 Schizophrenia Market Analysis Overview at a Glance

5 Executive Summary of Schizophrenia

6 Schizophrenia Epidemiology and Market Methodology

7 Schizophrenia Epidemiology and Patient Population

8 Schizophrenia Patient Journey

9 Schizophrenia Treatment Algorithm, Schizophrenia Current Treatment, and Medical Practices

10 Key Endpoints in Schizophrenia Clinical Trials

11 Schizophrenia Marketed Therapies

12 Schizophrenia Emerging Therapies

13 Schizophrenia: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Schizophrenia

16 Schizophrenia Market Key Opinion Leaders Reviews

18 Schizophrenia Market Drivers

19 Schizophrenia Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Schizophrenia Epidemiology 2034

DelveInsight's "Schizophrenia - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Schizophrenia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Schizophrenia Pipeline 2024

"Schizophrenia Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Schizophrenia market. A detailed picture of the Schizophrenia pipeline landscape is provided, which includes the disease overview and Schizophrenia treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=schizophrenia-market-expected-to-rise-2034-boehringer-ingelheim-karuna-therapeutics-acadia-pharmaceuticals-reviva-pharmaceuticals-sunivionpsychogenics-otsuka-pharmaceuticals-neurocrine-biosc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.